138 related articles for article (PubMed ID: 10834304)
1. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome.
Rubino T; Massi P; Viganò D; Fuzio D; Parolaro D
Life Sci; 2000 Apr; 66(22):2213-9. PubMed ID: 10834304
[TBL] [Abstract][Full Text] [Related]
2. Precipitated and spontaneous withdrawal in rats tolerant to anandamide.
Costa B; Giagnoni G; Colleoni M
Psychopharmacology (Berl); 2000 Apr; 149(2):121-8. PubMed ID: 10805606
[TBL] [Abstract][Full Text] [Related]
3. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction.
Mas-Nieto M; Pommier B; Tzavara ET; Caneparo A; Da Nascimento S; Le Fur G; Roques BP; Noble F
Br J Pharmacol; 2001 Apr; 132(8):1809-16. PubMed ID: 11309253
[TBL] [Abstract][Full Text] [Related]
4. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats.
Navarro M; Chowen J; Rocío A Carrera M; del Arco I; Villanúa MA; Martin Y; Roberts AJ; Koob GF; de Fonseca FR
Neuroreport; 1998 Oct; 9(15):3397-402. PubMed ID: 9855288
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
6. Functional interaction between opioid and cannabinoid receptors in drug self-administration.
Navarro M; Carrera MR; Fratta W; Valverde O; Cossu G; Fattore L; Chowen JA; Gomez R; del Arco I; Villanua MA; Maldonado R; Koob GF; Rodriguez de Fonseca F
J Neurosci; 2001 Jul; 21(14):5344-50. PubMed ID: 11438610
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
[TBL] [Abstract][Full Text] [Related]
8. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
Cook SA; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
[TBL] [Abstract][Full Text] [Related]
9. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
10. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
Beardsley PM; Martin BR
Eur J Pharmacol; 2000 Jan; 387(1):47-53. PubMed ID: 10633159
[TBL] [Abstract][Full Text] [Related]
11. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
Tsou K; Patrick SL; Walker JM
Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
[TBL] [Abstract][Full Text] [Related]
12. Blockade by the cannabinoid CB(1) receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats.
Serra S; Brunetti G; Pani M; Vacca G; Carai MA; Gessa GL; Colombo G
Eur J Pharmacol; 2002 May; 443(1-3):95-7. PubMed ID: 12044797
[TBL] [Abstract][Full Text] [Related]
13. Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons.
Hampson RE; Simeral JD; Kelly EJ; Deadwyler SA
Hippocampus; 2003; 13(5):543-56. PubMed ID: 12921345
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
Aceto MD; Scates SM; Lowe JA; Martin BR
Eur J Pharmacol; 1995 Aug; 282(1-3):R1-2. PubMed ID: 7498260
[TBL] [Abstract][Full Text] [Related]
15. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Tanda G; Loddo P; Di Chiara G
Eur J Pharmacol; 1999 Jul; 376(1-2):23-6. PubMed ID: 10440085
[TBL] [Abstract][Full Text] [Related]
16. Spinal modulation of calcitonin gene-related peptide by endocannabinoids in the development of opioid physical dependence.
Trang T; Ma W; Chabot JG; Quirion R; Jhamandas K
Pain; 2006 Dec; 126(1-3):256-71. PubMed ID: 16935424
[TBL] [Abstract][Full Text] [Related]
17. Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?
Caberlotto L; Rimondini R; Hansson A; Eriksson S; Heilig M
Neuropsychopharmacology; 2004 Jan; 29(1):15-22. PubMed ID: 12968131
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and kinetics of loss of tolerance and physical dependence on morphine induced by pellet implantation in the rat.
Villar VM; Bhargava HN
Pharmacology; 1992; 45(6):319-28. PubMed ID: 1488454
[TBL] [Abstract][Full Text] [Related]
19. Two distinctive antinociceptive systems in rats with pathological pain.
Mao J; Price DD; Lu J; Keniston L; Mayer DJ
Neurosci Lett; 2000 Feb; 280(1):13-6. PubMed ID: 10696800
[TBL] [Abstract][Full Text] [Related]
20. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
Yamaguchi T; Hagiwara Y; Tanaka H; Sugiura T; Waku K; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2001 Aug; 909(1-2):121-6. PubMed ID: 11478928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
